Please login to the form below

Not currently logged in
Email:
Password:

Crohn's disease

This page shows the latest Crohn's disease news and features for those working in and with pharma, biotech and healthcare.

AbbVie says Allergan takeover delayed by FTC verdict

AbbVie says Allergan takeover delayed by FTC verdict

position. There’s no specified timeline for that review to complete, but AbbVie says it has “entered into a timing agreement with FTC staff that would likely result” in a ... AZ licensed the drug – which is in late-stage testing for ulcerative

Latest news

More from news
Approximately 20 fully matching, plus 151 partially matching documents found.

Latest Intelligence

  • Case study: 4 Sites – Navigating the course ahead Case study: 4 Sites – Navigating the course ahead

    Client:SCITERION. Agency:N/A. Campaign:4 Sites: Navigating the course ahead. Timescale:N/A. Crohn’s disease – a chronic, debilitating and progressive disease – is on the increase worldwide, but remission

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The first test of this will be Shire’s new blockbuster-in-waiting Takhzyro, which gained EMA approval in November, for the rare disease hereditary angioedema (HAE). ... Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other

  • Deal Watch October 2018

    Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... Roche has an existing agreement with Ionis for IONIS‐HTTRx, an antisense drug for Huntington’s Disease, and the new deal is to

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    Pipeline problems. The Commission’s novel approach has its roots in pharma mergers. ... Specifically, Hospira was selling Inflectra, an infliximab biosimilar used to treat several chronic inflammatory diseases, notably the inflammation of Crohn’s

  • Deal Watch January 2018

    for local administration for the treatment of complex perianal fistulas in patients with Crohn’s disease.  The companies were already partners having signed a $432m licensing deal in July 2016 for ... Option exercise (2 options). 640. TiGenix/Takeda.

More from intelligence
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest appointments

  • TiGenix appoints Dr Marie Paule Richard TiGenix appoints Dr Marie Paule Richard

    in phase III trials for complex perianal fistulas in Crohn's disease.

  • Ex J&J VP joins board of Immune Ex J&J VP joins board of Immune

    Immune will benefit from Durrant's knowledged of the iundstry gained during time in roles such as worldwide VP at Johnson &Johnson and VP, Pharmacia until its acquisition by Pfizer. ... Its lead product candidate is bertilimumab, which is in clinical

  • Former Novartis president joins Qu Biologics Former Novartis president joins Qu Biologics

    His senior industry experience will support Qu Biologics' plans to advance the development of its investigational immunotherapies for treatments such as Crohn's disease. ... Bob Pelzer's wealth of leadership experience with Novartis and DuPont will be

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
GCI Health

GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...

Latest intelligence

COVID-19 is redefining the value of ‘critical jobs’: An opportunity for social care?
...
How to keep your weight under control during lockdown
...
Brands stepping up to show solidarity during COVID-19
The brands that are stepping up to show solidarity during COVID-19 will be those that are remembered long after pandemic passes....

Infographics